Drug
Caba 201
Caba 201: highest development phase Phase 2/3, developed by Cabaletta Bio. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Cabaletta Bio
Trials
| Drug | Phase | Indication |
|---|---|---|
| CABA-201 NCT06328777 | Phase 2/3 | Systemic Sclerosis |
| CABA-201 NCT06359041 | Phase 1/2 | Generalized Myasthenia Gravis (gMG) |
| CABA-201 NCT06121297 | Phase 1/2 | Systemic Lupus Erythematosus |
| CABA-201 NCT07006805 | Phase 1/2 | Relapsing Multiple Sclerosis (RMS) |
Latest
No recent events.
Follow Caba 201 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.